venetoclaxibrutinibzanubrutinibacalabrutinibBTKiBCL2ichronic lymphocytic leukaemiaCLL
…brutinib (40.7%), acalabrutinib (30.5%), zanubrutinib (3.4%) or venetoclax (25.4%). 91.5% of them had at least one comorbidity and the med…
1articles mentioning drugs
2drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: BCL2i ×
BCL2i
This drug is selected. Its supporting articles are shown below.